Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

Chronic lymphocytic leukaemia (CLL) is characterised by a heterogeneous clinical course. Such heterogeneity is associated with a number of markers, including TP53 gene inactivation. While TP53 gene alterations determine resistance to chemotherapy, it is not clear whether they can influence early dis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sci Rep
Hauptverfasser: Monti, Paola, Lionetti, Marta, De Luca, Giuseppa, Menichini, Paola, Recchia, Anna Grazia, Matis, Serena, Colombo, Monica, Fabris, Sonia, Speciale, Andrea, Barbieri, Marzia, Gentile, Massimo, Zupo, Simonetta, Dono, Mariella, Ibatici, Adalberto, Neri, Antonino, Ferrarini, Manlio, Fais, Franco, Fronza, Gilberto, Cutrona, Giovanna, Morabito, Fortunato
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595214/
https://ncbi.nlm.nih.gov/pubmed/33116240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-75364-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge